Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

著者: Thomas A. Hope, Emily K. Bergsland, Murat Fani Bozkurt, Michael M. Graham, Anthony P. Heaney, Ken Herrmann, James R. Howe, Matthew H. Kulke, Pamela L. Kunz, Josh Mailman, Lawrence May, David C. Metz, Corina Millo, M. Sue O’Dorisio, Diane Reidy‐Lagunes, Michael C. Soulen, Jonathan Strosberg - Journal of Nuclear Medicine 2017 被引用: 351

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used